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Abstract 
Ischaemic conditioning is the phenomenon of protection against reperfusion injury via the application 
of brief, repeated episodes of non-lethal ischaemia. This review has three aims: 1) to briefly explain 
the various categories of ischaemic conditioning; 2) to explore past clinical trials and their failures; 3) 
to explore the future of clinical trials in the realm of ischaemic conditioning.  
Introduction 
Protecting the myocardium against lethal ischaemia necessitates rapid reperfusion. Paradoxically 
however, reperfusion injures the myocardium, a phenomenon known as “ischaemia-reperfusion 
injury” (IRI). There is currently no effective clinical intervention for IRI in spite of the fact that it may 
contribute up to 50% of final myocardial infarct (MI) size1. This review intends to describe past, 
present, and future clinical trials into ischaemic conditioning, which present one of the few avenues 
currently being explored clinically to kerb IRI. 
The Principles of Ischaemic Conditioning and the Supporting Proof-of-Concept Studies 
Ischaemic Conditioning is a form of protection against IRI produced via brief cycles of non-lethal 
ischaemia. These cycles may be sub-classified thusly (see also figure 1): 
 Pre-conditioning 
o Classical Ischaemic Pre-conditioning (IPC): brief cycles of non-lethal ischaemia 
induced locally and directly to the myocardium prior to an episode of lethal ischaemia, 
e.g. aortic clamping. IPC has been shown to reduce post-surgical markers of 
cardiovascular damage (e.g. ATP2, Troponin T3) when performed during coronary 
artery bypass surgery (CABG). However, due to the inherent embolic risk of such 
intervention, it has not been carried over to large-scale clinical trials. 
o Remote Ischaemic Pre-conditioning (RIPC): brief cycles of non-lethal ischaemia 
induced at a “remote” limb via blood pressure cuff prior to an episode of lethal 
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myocardial ischaemia. The need to apply the conditioning prior to an ischaemic 
stimulus largely limits its application to the surgical arena where the time of onset of 
the injurious ischaemia can be readily predicted. Proof-of-concept studies have shown 
that RIPC has the capacity to reduce post-CABG troponin release in humans.4,5 Such 
an intervention is an attractive prospect due to its non-invasive nature. However, the 
recent outcome trials, RIPHEART and ERICCA, have been neutral and will be explored 
later in this review. 
 Per-Conditioning 
o Pharmacological Per-conditioning (PPerC): the use of pharmaceutical agents to 
mimic a conditioning stimulus during an ischaemic insult to protect against 
subsequent reperfusion injury. Proof-of-concept studies have shown cyclosporine-A 
(CsA)6 and metoprolol7 to be associated with a significant reduction in infarct size 
(measured by late-gadolinium enhancement on cardiac MRI). However, the large-
scale CsA-based CIRCUS and CYCLE studies have also been neutral and are discussed 
in the next section (“The Failure of Large-Scale Ischaemic Conditioning Trials”). 
o Remote Ischaemic Per-conditioning (RIPerC): brief cycles of non-lethal ischaemia 
induced at a limb via blood pressure cuff during an episode of lethal myocardial 
ischaemia. The proof-of-concept ERIC-LYSIS8 study randomised ST-elevation 
myocardial infarction (STEMI) patients to receive thrombolysis with or without 
RIPerC. The RIPerC cohort had a significant reduction in MI size 24 hours post-
intervention. This was shown by a median 32% reduction in troponin-T (P = 0.020), 
and 19% reduction in creatinine kinase (P = 0.026) levels. The proof-of-concept 
CONDI9 trial randomised STEMI patients to receive PPCI with or without in-ambulance 
RIPerC. The RIPerC cohort had a significant reduction in all-cause mortality (P = 0.027) 
on follow-up (median = 3.8 years). The large-scale CONDI2/ERICPPCI studies are 
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underway and will be discussed in the final section (“The Future of Clinical Trials in 
Ischaemic Conditioning”). 
 Post-conditioning 
o Pharmacological Post-conditioning (PPost): the use of pharmaceutical agents to 
mimic a conditioning stimulus following onset of reperfusion to reduce subsequent 
reperfusion injury. The J-WIND study of 569 MI patients10 showed that those given an 
atrial natriuretic peptide (ANP) infusion post-reperfusion had a significantly reduced 
infarct size of 14.7% (P = 0.019) and a reduced incidence of readmission for heart 
failure relative to the control group (median follow-up period = 2.7 years) (HR = 0.267; 
P = 0.011). This same study showed that nicorandil had no effect on infarct size. In a 
study of 172 STEMI patients,11 exenatide (glucagon-like-peptide-1 analogue) infusion 
during reperfusion attenuated myocardial infarction, resulting, on average, in a 15% 
greater salvage index (i.e. the difference between actual and potential infarct size). In 
spite of this however, no significant change in clinical outcome between the two 
cohorts was found. 
o Classical Ischaemic Post-conditioning (IPost): brief cycles of non-lethal ischaemia 
applied following angioplasty of the culprit lesion, typically achieved via transient 
balloon inflation within the culprit vessel. Proof-of-concept studies have produced 
mixed results12,13 and the large-scale DANAMI 3-iPost (data presented at the American 
College of Cardiology 2016) clinical trial showed no significant difference in clinical 
outcomes. This trial will be explored in the next section (“The Failure of Large-Scale 
Ischaemic Conditioning Trials”). 
o Remote Ischaemic Post-conditioning (RIPost): brief cycles of non-lethal ischaemia 
induced at a limb via blood pressure cuff following reperfusion therapy. Whilst proof-
of-concept studies have shown some promise14, no large-scale clinical trials have yet 
been undertaken to explore RIPost. 
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The Failure of Large-Scale Ischaemic Conditioning Trials 
Whilst proof-of-concept studies have provided a tantalising view of potential clinical efficacy with 
various ischaemic conditioning interventions, large-scale clinical trials have so far proved fruitless. This 
section will explore these failed trials and examine why ischaemic conditioning techniques have yet 
to fulfil their clinical potential. 
 RIPC – The 2015 RIPHeart (“A Multicentre Trial of Remote Ischaemic Preconditioning for Heart 
Surgery) study15 by Meybohm et al was a 1403 patient, multicentre, double-blinded, 
randomised controlled trial (RCT) exploring RIPC in elective surgical patients requiring cardiac 
bypass. The primary end-point was a composite of acute renal failure, stroke, non-fatal MI or 
all-cause death up to 14 days after surgery. Four cycles of true or sham RIPC were given post-
anaesthetic induction and pre-surgical incision. No significant difference was seen between 
the primary end-points of either cohort. At approximately the same time, the ERRICA (“The 
Effect of Remote Ischaemic Conditioning on Clinical Outcomes in Coronary Artery Bypass Graft 
Surgery”) study16 by Yellon et al was published. This study was a 1612 patient, multicentre, 
double-blinded RCT of RIPC in patients undergoing CABG surgery. The primary end-point was 
the rate of major adverse cardiac and cerebral events 12 months after the intervention. Four 
cycles of true or sham RIPC were given post-anaesthetic induction and pre-surgical incision. 
Once again, no significant difference was seen between the primary end-points of either 
cohort.  
Why was it that both of these trials failed to provide positive results? It may be that the injury 
suffered during CABG surgery is too small for RIPC to provoke a significant protective effect: 
it is well recognised from the pre-clinical literature that the smaller the primary injury, the 
smaller the benefit from a conditioning intervention is likely to be. It is also important to 
consider the other therapies patients undergoing surgical procedures will be exposed to: all 
patients in RIPHeart and >90% of patients in ERICCA were anaesthetised with propofol, an 
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agent which might in-fact abolish RIPC-based cardio-protection and an important potential 
confounder17.  
 PPerC – The 2015 CIRCUS (“Cyclosporine to ImpRove Clinical oUtcome in ST-elevation 
Myocardial Infarction Patients”) study18 by Cung et al was a 970 patient, multicentre, double-
blinded RCT exploring CsA as a preconditioning agent in patients undergoing PPCI to treat 
STEMI. The primary end point was a 1- and 3-year composite of heart failure progression, 
rehospitalisation for heart failure, adverse left ventricular modelling, and all-cause death. 
Prior to PPCI, patients were randomised to a CsA or placebo infusion. No significant difference 
in the primary end point was seen at 1 year: a neutral outcome. This could be due to the 
absence of data for LV end-diastolic volume in 17% of patients. This absent data, combined 
with the high incidence of adverse modelling in both cohorts, could have made it difficult to 
detect a significant difference in the other components of the primary end point composite. 
The 2016 CYCLE (“CYCLosporinE A in Reperfused Acute Myocardial Infarction”) study19 by 
Ottani et al was a 410 patient, multicentre, Prospective/Randomised/Open-label/Blinded-
Endpoint (PROBE) trial which also explored CsA as a perconditioning agent in patients 
undergoing PPCI to treat STEMI. The primary end point was the incidence of ≥70% ST-segment 
resolution 60 min after Thrombolysis in Myocardial Infarction (TIMI) flow grade 3. Prior to 
PPCI, patients were randomised to a CsA or placebo injection. Once again, no significant 
difference between the cohorts was detected. As such, the future use of CsA as a per-
conditioning agent appears doubtful. 
 IPost – DANAMI 3-iPost (“DANish Study of Optimal Acute Treatment of Patients with ST-
segment Elevation Myocardial Infarction) is a treatment subgroup of a 2016 trial programme 
comparing multiple treatment strategies for STEMI. The iPost arm of the trial was a 1234 
patient, multicentre, PROBE trial comparing standard PCI to PCI plus IPost. The primary end 
point was a composite of hospitalisation for heart failure and all-cause death within 2 years. 
Patients were randomised to PCI, or PCI plus four 30-second balloon inflations within the 
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reperfused coronary artery following initial reperfusion. No significant difference was 
detected between the two cohorts (data presented at the American College of Cardiology, 
2016). The duration of ischaemia is critical: in the pre-clinical literature, there is a clear 
“therapeutic window”: ischaemic post-conditioning is ineffective where the index ischaemia 
duration is either very short or very long20 and it would seem that in clinical trials, the 
therapeutic window is typically in the order of 1-4 hours from symptom onset to 
revascularisation. Whether or not ischaemic time played a role in the neutral DANAMI 3-iPost 
study will require further analysis upon official publication.  
The Future of Clinical Trials in Ischaemic Conditioning 
A number of large outcome trials exploring ischaemic conditioning are currently underway and may 
yet still provide evidence for the introduction of conditioning techniques into clinical practice. 
RIPerC in Primary PCI 
The CONDI 2 (Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI) and ERIC-PPCI 
(Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI) 
are a pair of collaborative studies investigating the use of RIPerC in STEMI patients.21 The studies are 
both multicentre, multinational, double-blinded RCTs with 2300 patients and 2000 patients 
respectively. Both trials share identical primary endpoints of hospitalisation for heart failure or 
cardiovascular mortality at 1 year. In these trials, STEMI patients will be randomised to PPCI with or 
without RIPerC. The RIPerC will be delivered either in-ambulance or on arrival to the PPCI centre 
depending on average national transit time. The results of these trials are hoped to be released in 
approximately 18 months. 
RIPerC in Thrombolysis 
Though the ERIC-lysis8 study provided evidence for clinically applied RIPerC, no large-scale trials have 
explored RIPerC in STEMI patients treated with thrombolysis. Whilst thrombolysis as an intervention 
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has largely been superseded by pPCI in the developed world, in the developing world thrombolysis is 
remains an important first-line therapy for STEMI. Large-scale human trials are still needed to provide 
evidence for a cost-neutral, life-saving therapeutic adjunct to thrombolysis.  
PPerC in pPCI 
Though the aforementioned CIRCUS18 study of PPerC was neutral at 1 year, the trial has not yet 
completed follow-up. It may yet show an effect of CsA at the 3-year end-point and as such, full 
conclusions may not currently be drawn.  It is also worth noting that CsA is not the sole 
pharmacological agent: there are multiple potential pharmacological targets within the increasingly 
well characterised cell-death pathway that may yet yield an efficacious PPerC option. Indeed, re-
purposing existing cardiovascular drugs may yield significant benefit to improve cardiovascular 
outcomes following an acute myocardial infarction. 
Conclusion 
Reperfusion injury plays a significant role in the evolution of the final myocardial infarct size yet 
physicians have no effective tools with which to combat the phenomenon. Recent small-scale human 
trials exploring the variety of ischaemic-conditioning modalities have shown some promise. If large-
scale trials can provide the evidence, reperfusion injury may yet become amenable to treatment. In 
remote conditioning exists a potentially cheap and non-invasive method of therapy, but as with 
pharmacological conditioning, the holy grail of an effective clinical intervention against IRI has yet to 
be realised. However, the search for an effective adjunct to reperfusion, if successful, will be well-
rewarded by further reductions in cardiovascular mortality and morbidity and the consequent 
reduction upon the burgeoning socioeconomic healthcare burden worldwide. 
 
Figure legends 
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Figure 1: Cartoon summarising the various forms of conditioning – ischaemic, remote and 
pharmacological – and the terminology relative to the onset of injurious ischaemia and 
subsequent reperfusion. Modalities applied prior to injurious ischaemia are termed 
“preconditioning”. A modality applied during the ischaemic injury is “perconditioning”. 
Any modality applied following the restoration of blood flow and reperfusion is regarded 
as “postconditioning”.  
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